American Thoracic Society - Sanofi Investor Call
Potential to address remaining unmet need asthma
with disruptive first-in-class assets.
sanofi
Amlitelimab
OX40L
Rilzabrutinib
BTKi
SAR'765
IL13xTSLP
•
Antibody
Non-depleting anti-OX40L addresses
both T2 and non-T2 inflammation to meet
patient need for broader high efficacy
Long-term disease control / potential
disease modification, infrequent dosing
•
Small molecule
Oral therapy being targeting type
2 and non-T2 pathways
Potential to establish pre-biologic
space and expand treatment of
moderate asthma patients
Phase 2b asthma readouts in 2024
•
NanobodyⓇ VHH molecule
Bispecific NanobodyⓇ VHH against
both TSLP and IL-13
Potential for breakthrough efficacy
Long-term disease control/potential
disease modification
Phase 1b asthma data
Amlitelimab, rilzabrutinib and SAR'765 are under investigation and not yet approved by any regulatory agency.
39 ATS Investor CallView entire presentation